Introduction {#sec1}
============

It has been known for more than 25 years that angiotensin IV (Ang IV, **1**; [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), a degradation product of the vasoactive peptide angiotensin II, enhances memory and learning in rodents after intracerebroventricular administration.^[@ref1]−[@ref8]^ Thus, the degradation leads to a bioactive hexapeptide with very different biological activity from that of the parent octapeptide.^[@ref9],[@ref10]^ In 2001, the membrane-bound insulin-regulated aminopeptidase (IRAP, oxytocinase, EC 3.4.11.3) was identified as a binding site for Ang IV,^[@ref11]^ a potent inhibitor of IRAP, as is LVV-hemorphin-7, which is formed by degradation of β-globin.^[@ref12],[@ref13]^ The M1 aminopeptidase, IRAP, is found in brain structures associated with cognitive, sensory, and motor functions along with other biological functions such as antigenic peptide generation for MHC Class I for cross-presentation,^[@ref14],[@ref15]^ translocation of GLUT4,^[@ref16]^ and oxytocin and vasopressin levels in the brain. The extracellular region of IRAP contains the catalytic site and is highly homologous to two other M1 aminopeptidase family members, endoplasmic reticulum aminopeptidase 1(ERAP1) and 2(ERAP2).^[@ref17]^ These three enzymes constitute the so-called antigen processing aminopeptidases anticipatory postural adjustments (APAs), in charge of trim antigenic peptides that will ultimately be used to modulate adaptative response, therefore being potential drug targets for the regulation of immune responses.^[@ref18]^ Although the poli-inhibition of several APAs is a good starting point in pharmaceutical development in this respect, low selectivity between the three APAs limits the clinical development. From the existing hypotheses to explain the effects of Ang IV in vivo,^[@ref19]−[@ref21]^ the one that attracted the most attention is that Ang IV and its analogues enhance cognitive functions through IRAP inhibition, resulting in altered levels of neuropeptides in the brain and/or facilitating glucose uptake in neurons by regulating GLUT4 translocation.^[@ref21]−[@ref23]^ The last factor is in line with the well-known enhancement of cognitive performance by glucose^[@ref24]^ and is reinforced by the fact that IRAP inhibitors do not alter glucose handling in normal and diabetic rats.^[@ref25]^ Endogenous substrates of IRAP, such as macrocyclic peptides oxytocin (**2**) and vasopressin (**3**), which encompass a disulfide element adjacent to the cleavage site of the ring system ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), are known to exert favorable influences on cognitive parameters in the brain.^[@ref23],[@ref26]^

![IRAP inhibitors and substrates: hexapeptide IRAP inhibitor Ang IV (**1**), macrocyclic IRAP substrates oxytocin (**2**) and vasopressin (**3**), macrocyclic IRAP inhibitor HA-08 (**4**), and cognitive enhancer dihexa (**5**) that binds to hepatocyte growth factor (HGF). Compounds **6**--**8** are low-molecular-weight IRAP inhibitors, not derived from the structure of Ang IV.](ao-2018-00595y_0009){#fig1}

Our labs are engaged in a collaborative program aimed at identifying inhibitors of IRAP as a possible new class of cognitive enhancers.^[@ref27]−[@ref31]^ Although several potent linear Ang IV analogues have previously been reported,^[@ref32]−[@ref35]^ we have previously reported a large series of cyclic peptides and pseudopeptides;^[@ref36]−[@ref41]^ particularly interesting among these were the macrocyclic analogs, mimicking the N-terminal fragment of Ang IV, and the IRAP-specific substrates oxytocin and vasopressin, from which compound HA-08 (compound **4**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) emerges as a very potent inhibitor of the enzyme (IC~50~ = 8.6 nM; *K*~i~ = 3 nM).^[@ref38]^ The biological characterization of this compound demonstrates that it affects the morphology of dendritic spines from rat hippocampal primary cultures and increases the number of stubby/mushroomlike spines, a property associated with improvement of memory and cognitive functions.^[@ref30]^ However, this and related macrocyclic inhibitors are still peptidic molecules, likely to be associated with pharmacokinetic problems such as limited blood--brain barrier (BBB) permeation. Notably, a dipeptide derivative from Ang IV, known as Dihexa (compound **5**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), which increases dendritic spine density and serves as a powerful cognitive enhancer in animal models, is able to cross the BBB. However, it remains unclear whether this molecule is an IRAP inhibitor, and to date, there is only evidence that this peptide binds to the hepatocyte growth factor (HGF).^[@ref42],[@ref43]^

The first series of druglike IRAP inhibitors reported comprises a benzopyran scaffold. The benzopyran, HFI-419 (Compound **6**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), represents one example of the promising compounds from this class.^[@ref27],[@ref44]^ The inhibitors from the HFI series were identified through in silico screening and are proven to be effective as cognitive enhancers in both normal and memory-deficit rat models.^[@ref44]−[@ref46]^ The 3,4-diaminobenzoic acid derivative **7** is an example of another class of compounds able to efficiently inhibit IRAP, showing in this case moderate selectivity versus ERAP1 and ERAP2.^[@ref47]^ More recently, very potent IRAP inhibitors relying on efficient zinc coordination through a phosphinic group were disclosed.^[@ref48],[@ref49]^

We previously screened 10 500 low-molecular-weight druglike compounds in an enzyme inhibition assay with IRAP from Chinese hamster ovary (CHO) cells,^[@ref50]^ from which compound **8** and related sulfonamides ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) were identified as a novel class of druglike IRAP inhibitors.^[@ref51]^ Two analogs from this series were further evaluated and found to alter the morphology and increase the density of dendritic spines of hippocampal cells from mice.^[@ref31]^ By means of exhaustive docking and free energy calculations, we identified two binding orientations compatible with the experimental data there reported.^[@ref31]^ Encouraged by these results, we herein expanded the sulfonamide collection with a series of fluoro atom substituted derivatives and report the capacity of the resulting expanded series (**8**--**34**, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) to inhibit recombinant human IRAP expressed in membranes of human embryonic kidney cells (HEK293). The fluorinated series exhibits high metabolic stability in microsomes and encompasses compounds with submicromolar affinity. The binding modes previously identified were thoroughly examined here with molecular dynamics (MD)-related methods for binding affinity estimation for the whole series of aryl sulfonamides. Thus, absolute binding free energies were obtained for each binding mode with the linear interaction energy (LIE) method, followed by calculations of relative binding free energies between six pairs of compounds using free energy perturbation (FEP) protocols. The results of this computational analysis clearly identify one binding mode, which specifically explains the structure--activity relationship (SAR) data and allows for elucidation of the molecular details involved in ligand binding to the protease.

###### Inhibitory Activities and Metabolic Stability of the Sulfonamide Series in IRAP

![](ao-2018-00595y_0007){#fx1}

IC~50~ was evaluated in an enzyme assay comprising recombinant human IRAP, transiently transfected in HEK293 cells, where a structural analog of **6** was used as control exhibiting an IC~50~ value of 5.29 μM.

Stabilities (*t*~1/2~, min) in human liver microsomes (HLMs) and mouse liver microsomes (MLMs) were measured for compounds **21** and **25**--**34**. ND = not determined.

Results and Discussion {#sec2}
======================

Chemistry {#sec2.1}
---------

Compounds **8**--**26** were prepared according to methods previously described.^[@ref51],[@ref52]^ Trichloro compound **27** and fluoro compounds **28**--**34** were prepared from 3-amino phenyltetrazole and the corresponding arylsulfonyl chloride to deliver the aryl sulfonamides, as shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}.

![Reagents: DCM, Pyridine; 25 °C, 16 h](ao-2018-00595y_0006){#sch1}

IRAP Inhibition and SAR {#sec2.2}
-----------------------

The ability of compounds **8**--**34** of inhibiting the catalytic activity of recombinant human IRAP was examined in transiently transfected HEK293 cells; the results are summarized in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. The data confirms the same SAR trend as previously observed from a smaller series of sulfonamides tested in CHO cells, that is, containing the hamster enzyme,^[@ref51]^ although somewhat lower IC~50~ values were encountered with the human IRAP assay ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00595/suppl_file/ao8b00595_si_001.pdf), Supporting Information). Sulfonamides **25** and **26**, which were previously shown to enhance the density of dendritic spines in primary hippocampal neuron cultures from mice,^[@ref31]^ show IC~50~ values of 0.74 μM (vs 3.1 μM in CHO cells) and 0.54 μM (vs 2.9 μM), respectively. Among the general SAR observations, the negative charge of the tetrazole ring seems essential for IRAP inhibition because methylation of the acidic NH position was deleterious for activity (cf. **8** and **9**). A similar negative effect was observed by replacement of the tetrazole by a methylamide group (cf. **10** and **9**). The integrity of the sulfonamide linker seems essential for IRAP affinity, as suggested by the 10-fold drop in binding affinity after methylation of the acidic NH group (cf. **8** and **11**) or the complete lack of inhibitory activity of the corresponding amide-derivative **12**. A thiophene ring is admitted only if it is halogenated, as is the case of dichloro substituted inhibitor **13**, showing submicromolar activity, as opposed to inactive, unsubstituted derivative **14**. Pyridine derivative **15** is also devoid of IRAP activity, whereas the benzene derivative, which also displayed no inhibitory activity applying the previous assay, is here shown to moderately inhibit the human IRAP (IC~50~ = 14.5 μM). Bicyclic derivatives are well tolerated; see compounds **17**, **18**, **19**, and particularly submicromolar benzoxadiazole **21**. However, biphenyl derivative **20** is totally inactive, indicating some restriction in the binding cavity accommodating this substitution. To assess the halogenation on the phenyl ring, the previous set of derivatives of compound **16** (containing **22**--**26**, all of which show promising IC~50~ values below 10 μM) was here expanded with compounds **27**--**34**. As expected, most compounds show an important improvement compared to that of the reference unsubstituted **16**, with compounds **25**, **26**, and **29** showing the same submicromolar potency as that of benzoxadiazole **21**.

Stability in Liver Microsomes {#sec2.3}
-----------------------------

The most potent sulfonamides, together with the new series of derivatives (**21**, **25**--**34**), were selected for characterization of their stability against oxidative metabolism. Stability was assessed using liver microsomes from human liver (HLM) and from mouse (MLM) applying a protocol previously reported.^[@ref53]^ All compounds evaluated exhibited a high stability in the microsome assays with the exception of **25** and **30**, which were degraded fast in HLM (*t*~1/2~ of 2 and 4 min, respectively), as shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. This observation can be most likely attributed to a human enzyme-specific benzylic oxidation of the para methyl groups of **25** and **30**, and the meta methyl derivative **31** was significantly less prone to decomposition (*t*~1/2~ = 600 min).

MD and LIE Calculations {#sec2.4}
-----------------------

In a previous attempt to understand the binding mode of inhibitors **21**, **25**, and **26**, a pool of possible binding orientations was initially generated by exhaustive docking of compound **26**. Each pose was subject to MD simulations, coupled to binding affinity estimation with the LIE method^[@ref54],[@ref55]^ for the three compounds in the series. Two alternative binding modes, pose A and pose B, were compatible with the experimental ranking in affinities within this limited subset.^[@ref31]^ One of the sulfone oxygens coordinates the Zn^2+^ ion in both binding modes, which otherwise are flipped with respect to each other in a way that the position of the aryl (or heteroaryl) and phenyltetrazole moieties are switched between them ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). We herein built every complex consisting of the 27 sulfonamides (compounds **8**--**34** in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) in each of the two binding poses (A and B; see [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}) and performed a similar exploration with MD sampling coupled to the LIE estimation of binding affinities. Inactive compounds **9** and **10** were not considered because they are the only neural ones in the otherwise charged series of compounds (see below). All simulated compounds were stable in each of the two poses, where the key interactions of the sulfone oxygen, −NH, and tetrazole groups described below were maintained for the whole series in different independent replicate MD simulations. In pose A ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A), the ligand is further stabilized by interactions between its −NH group and Glu465. The tetrazole ring is accommodated in the cavity defined by the hinge loop between residues 438 and 443, dominated by polar interaction with the backbone of Arg439 and the side chain of Thr442. The heteroaryl substituent is facing the GAMEN loop (^428^Gly--Ala--Met--Glu--Asn^432^), a key structural motif that remains open during the MD simulations of the crystal structure considered,^[@ref30],[@ref56]^ allowing accommodation of most substitutions explored in the series. The alternate pose B ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B) places the heteroaryl group close to the 438--443 loop, and the tetrazole is coordinated to Arg439. This area is relatively solvent exposed, and the aforementioned interaction is sometimes bridged via a water molecule in the MD simulations. Additionally, the −NH group of the sulfonamide in this binding mode interacts with the carboxylate groups of Glu295 and Glu431 via a water molecule.

![Binding modes of compound **13** (orange) in the enzymatic cleft of human IRAP. (A) pose A; (B) pose B. Zn^2+^ and water molecules are shown as gray and red spheres, respectively, and chlorine atoms are represented in green. All of the figures shown are from 2 ns MD average structures.](ao-2018-00595y_0001){#fig2}

Binding free energies estimated with the LIE methodology are reported in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, and the values obtained in each pose are compared to the experimental values from HEK293 cells, as extracted from [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. Owing to the strong electrostatic ligand interactions with the Zn^2+^ ion, which is very sensitive to given force field parameters, it was found necessary in previous LIE calculations to empirically determine the electrostatic scaling factor β.^[@ref30],[@ref31],[@ref57]^ The same situation was, for example, encountered with saccharide binding to lectins in which the ligand interactions were dominated by coordination to calcium ions.^[@ref57]^ The earlier derived β-value of 0.19 for IRAP ligands^[@ref30],[@ref31]^ was, however, based on MD simulations with only three peptidic inhibitors. Still, it led to a good correlation between MD sampled energies---using both poses A and B---and CHO experimental affinities for the three sulfonamides recently characterized (**21**, **25**, and **26**). In the present series, **21** out of the **27** compounds have experimentally determined IC~50~ values, whereas compounds **9**, **10**, **12**, and **20** exhibit IC~50~ values \>1000 μM and compounds **14**--**15** have IC~50~ \> 100 μM. Hence, we selected this subset of **21** compounds in each binding mode (A and B) to optimize the LIE model by independent fitting of the β and γ parameters, while using the standard value of α = 0.181 (free parameterization of the last parameter did not improve the statistics). [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} shows the correlation between calculated and experimental affinities for the two binding modes, together with the corresponding optimized parameters and the calculated mean unassigned error (MUE). A similarly low value of β ≈ 0.1 is obtained in the two binding modes, which is likely due to the strong Zn^2+^ interactions as outlined above. Notably, the offset parameter, γ, which is only a constant (in kcal/mol) that does not affect relative binding free energies, is more negative for pose A than pose B. This indeed reflects overall more favorable interaction energies in the latter pose, which is particularly due to the electrostatic component of the binding free energy (Δ*G*~el~; see [Supporting Information Tables S1 and S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00595/suppl_file/ao8b00595_si_001.pdf)). Further, a modest correlation between Δ*G*~el,calc~ and Δ*G*~obs~ is only observed for pose B, which is indicative of more specific electrostatic interactions as compared to that for pose A (see [Supporting Information Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00595/suppl_file/ao8b00595_si_001.pdf)). The two models show reasonably good statistical performance, with MUEs of 0.54 (A) and 0.43 (B) kcal/mol. The slightly better performance for pose B is, however, barely significant considering that the experimental binding free energies only span 2.1 kcal/mol for the **21** compounds. The capacity of each model to reproduce the relative ranking within the series was also assessed with Pearson correlation coefficients, which again favor pose *B* (*R* = 0.64 compared to *R* = 0.36 for pose *A*). However, none of the models can completely capture the low affinity of nonbinders **12**, **14**, **15**, and **20**, which are overestimated in the two models ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}).

![Scatter plot of LIE-calculated (A, pose *A*; B, pose *B*) and experimental binding free energies of the sulfonamide series. The plots contain 21 data points, as the six compounds without a measured IC~50~ value are excluded from this quantitative evaluation.](ao-2018-00595y_0002){#fig3}

###### LIE-Calculated and Experimental Binding Free Energies of Sulfonamide Inhibitors in Complex with IRAP[a](#t2fn1){ref-type="table-fn"}^,^[b](#t2fn2){ref-type="table-fn"}

           LIE[b](#t2fn2){ref-type="table-fn"}                  
  -------- ------------------------------------- -------------- -----------------------------------------
  **8**    --7.70 ± 0.1                          --8.08 ± 0.2   --8.10 ± 0.1
  **11**   --8.44 ± 0.4                          --7.54 ± 0.2   --6.72 ± 0.1
  **12**   --8.22 ± 0.2                          --7.85 ± 0.2   \>−4.09[e](#t2fn5){ref-type="table-fn"}
  **13**   --7.64 ± 0.1                          --8.20 ± 0.1   --8.32 ± 0.1
  **14**   --7.44 ± 0.2                          --7.15 ± 0.2   \>−5.45[f](#t2fn6){ref-type="table-fn"}
  **15**   --7.04 ± 0.2                          --7.04 ± 0.2   \>−5.45[f](#t2fn6){ref-type="table-fn"}
  **16**   --6.88 ± 0.2                          --7.38 ± 0.2   --6.60 ± 1.3
  **17**   --7.57 ± 0.2                          --7.51 ± 0.1   --7.13 ± 0.2
  **18**   --7.35 ± 0.3                          --7.48 ± 0.1   --6.76 ± 0.1
  **19**   --7.46 ± 0.3                          --7.12 ± 0.1   --6.67 ± 0.2
  **20**   --7.66 ± 0.2                          --7.14 ± 0.2   \>−4.09[e](#t2fn5){ref-type="table-fn"}
  **21**   --8.08 ± 0.2                          --8.52 ± 0.2   --8.70 ± 0.1
  **22**   --7.62 ± 0.2                          --7.44 ± 0.1   --6.98 ± 0.1
  **23**   --7.26 ± 0.1                          --7.05 ± 0.1   --7.17 ± 0.1
  **24**   --7.64 ± 0.2                          --7.81 ± 0.1   --7.97 ± 0.1
  **25**   --7.43 ± 0.1                          --7.34 ± 0.1   --8.36 ± 0.0
  **26**   --7.51 ± 0.1                          --7.49 ± 0.2   --8.54 ± 0.1
  **27**   --8.04 ± 0.1                          --8.39 ± 0.1   --8.07 ± 0.2
  **28**   --7.45 ± 0.2                          --6.89 ± 0.1   --7.34 ± 0.1
  **29**   --7.34 ± 0.3                          --7.25 ± 0.2   --8.29 ± 0.1
  **30**   --7.43 ± 0.1                          --7.47 ± 0.1   --7.67 ± 0.1
  **31**   --7.78 ± 0.2                          --8.00 ± 0.2   --7.67 ± 0.0
  **32**   --7.77 ± 0.1                          --6.96 ± 0.1   --6.99 ± 0.0
  **33**   --6.91 ± 0.2                          --6.41 ± 0.2   --6.61 ± 0.0
  **34**   --6.94 ± 0.3                          --6.99 ± 0.2   --6.70 ± 0.2

Calculations based on pose *A* and pose *B*.

All energies are in kcal/mol, with standard error of the mean (SEM) for calculated (replicate simulations) and experimental (independent experiments) values.

Optimized LIE model, with α = 0.181, β = 0.1, γ = −6.43 for pose *A*.

α = 0.181, β = 0.07, and γ = −4.89 for pose *B*.

Experimental IC~50~ is \>1000 μM,

Experimental IC~50~ is \>100 μM. Neutral compounds **9**--**10**, which are also inactive, are excluded from the table as they do not obey our LIE parameterization derived for charged compounds.

Free Energy Perturbation Calculations {#sec2.5}
-------------------------------------

To confirm the indication of the LIE models that marginally favor pose B and further investigate the reasons for the low affinity of nonbinders, we designed a set of free energy perturbation (FEP) transformations for selected pairs of ligands. With this approach, one can estimate the relative binding free energies (ΔΔ*G*) between pairs of compounds and compare with the corresponding experimental shifts in binding affinities. A total of 10 ligands were considered in six pairs of FEP transformations, which were also carried out in parallel in both binding modes. These include nonbinders **9**, **12**, **14**, and **20**, which were selected to cover different structural changes affecting the affinity within the series. The results of the FEP calculations are summarized in [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} and [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}. The drastic effect observed by methylation of the tetrazole ring was examined by performing the transformation **8** ↔ **9**. In this case, pose *B* reproduces the experimental effect very accurately, which can be related to the loss of interactions with Arg439, leading to major rearrangements of the ligand ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). In contrast, in pose *A*, the tetrazole ring is buried toward the 438--443 loop, and the effect of methylation and the corresponding charge neutralization is instead predicted to be favorable for the affinity ([Supporting Information Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00595/suppl_file/ao8b00595_si_001.pdf)). Two pairs of perturbations were carried out to examine the drop of enzyme inhibition observed by variations of the sulfonamide linker: replacement of sulfonamide by an amide (**8** ↔ **12**) and methylation of the −NH group (**13** ↔ **11**). In the former case, the loss of binding affinity is due to the amide adopting a more energetically favorable trans conformation, leading to the loss of interactions in both poses *A* and *B* ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). More subtle and specific is the effect of methylation in compound **11** compared to that in unmethylated derivative **13**. The experimental 10-fold drop in affinity is only observed in the simulations of pose *B* ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} and [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}) and can be assigned to the loss of the interaction between NH and Glu431 conserved in this pose ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C). Note that in this case, we also evaluated the negligible effect on binding affinity of the Br/Cl transformation between this pair, correctly reproduced in the model of pose *B*. The remaining three FEP transformations examined the impact of modifications of the aryl moiety. The positive effect of halogenation on the thiophene (transformation **14** ↔ **13**) or the benzene rings (**23** ↔ **22**) was also exclusively reproduced in pose *B* ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} and [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). In the case of thiophene, the unsubstituted compound (**14**) is a nonbinder, in contrast to the sub-micrometer inhibitor bearing a 3,4-dichloro-2-thiophene (**13**). Notably, this effect is specifically captured by the FEP simulation in pose *B*, but was underpredicted in the corresponding LIE model. The FEP calculations of pose *B* are sensitive enough to detect the milder effect of fluorination in the orthoposition of the benzene ring (**23** ↔ **22**), which is explained by the optimized interactions of the aryl group with residues in the 438--443 loop. Finally, an intriguing transformation not captured in the LIE models referred to the introduction of a biphenyl ring in compound **16** to yield compound **20**, which led to an experimental loss of any inhibitory activity. This effect is indeed reproduced in the corresponding FEP simulation (**16** ↔ **20**) in pose *B*, where the substitution leads to a suboptimal fitting of the biphenyl in the narrow cavity defined by the 438--443 loop ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}F), which provides further evidence of the specificity of this binding model in explaining the SAR of the current series.

![Bar diagram showing relative binding free energies (ΔΔ*G*~bind~) of six pairs of compounds, calculated in poses *A* and *B* and compared to the corresponding experimental values). Energies are in kcal/mol, and errors bars denote SEM.](ao-2018-00595y_0003){#fig4}

![FEP transformations in pose *B*. Panels (A)--(F) show snapshots of starting and ending points for the given transformation. Zn^2+^ and water molecules are shown as gray and red spheres, respectively. Br, Cl, and F atoms are represented in pink, green, and light blue, respectively.](ao-2018-00595y_0004){#fig5}

###### Experimental and Calculated (FEP) Relative Binding Free Energies between Pairs of Sulfonamide Ligands

                    ΔΔ*G*~calc~ (kcal/mol ± SEM)                  
  ----------------- ------------------------------ -------------- -----------------------------------------------
  **9** → **8**     5.40 ± 0.4                     --4.86 ± 0.2   \<−4.01 ± 0.0[c](#t3fn3){ref-type="table-fn"}
  **8** → **12**    8.80 ± 1.0                     6.58 ± 1.6     \>4.01 ± 0.0[c](#t3fn3){ref-type="table-fn"}
  **11** → **13**   2.10 ± 0.3                     --1.69 ± 0.1   --1.60 ± 0.1
  **13** → **14**   --1.41 ± 0.5                   2.67 ± 0.6     \<2.87 ± 0.1[c](#t3fn3){ref-type="table-fn"}
  **22** → **23**   1.28 ± 0.1                     --0.91 ± 0.2   --0.19 ± 0.1
  **20** → **16**   6.06 ± 0.9                     --5.21 ± 1.2   \<−2.51 ± 1.3[c](#t3fn3){ref-type="table-fn"}

The arrow depicts the direction of the transformation, as set up in the corresponding FEP simulation, which determines the sign of the corresponding ΔΔ*G*~bind~.

The relative binding free energies (ΔΔ*G*~exp~) were calculated from experimentally determined IC~50~ values using the relation .

No experimental value could be determined (i.e., IC~50~ \> 100 μM), and the calculated ΔΔ*G*~exp~ represents the detection threshold.

IRAP Selectivity of Sulfonamides {#sec2.6}
--------------------------------

We have previously reported that sulfonamides **21**, **25**, and **26** are specific IRAP inhibitors, with much lower efficacy in inhibiting the activity of the homologous enzymes, aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H).^[@ref31]^ Our extended binding mode analysis of the whole series of sulfonamides on IRAP allows for interpretation of the selectivity. [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"} shows a superposition of the two IRAP-**26** complexes (pose *A* and pose *B*) with the crystal structures of APN (PDB code 4FYQ)^[@ref58]^ and LTA4H (PDB code 2VJ8).^[@ref59]^ The optimal complementarity between inhibitor **26** and the GAMEN loop of IRAP, which is maintained along the whole sulfonamide series, is in stark contrast to the GAMEN loop conformation found in APN and LTA4H. The conformation of the loop in the latter enzymes is clearly incompatible with the binding modes discussed herein. However, a similar conformation of the GAMEN loop was also observed in the latest crystal structure of IRAP in complex with the phosphinic derivatives. Although this may be a property of that particular inhibitor, one should not rule out the possibility that all potent inhibitors promote the "closing" of the active site, which should be acknowledged and discussed. We thus attempted to dock the series in this "closed" IRAP following our previous protocols with GLIDE.^[@ref30],[@ref31]^ The initial results did not show any conserved pose, and no inhibitor was able to make interactions with the Zn^+2^. This was still the case in a second round of constrained docking imposing interaction with the metal, a strategy that was useful with the "open" IRAP structure.^[@ref30],[@ref31]^ The current exploration reinforces the idea that these series of sulfonamides cannot access the binding site for competitive inhibition considering the closed conformation of the GAMEN loop, which might be stabilized by the phosphinic derivatives due to their increased conformational flexibility,^[@ref60]^ compared to the relatively rigid aryl sulfonamides here presented. Thus, the specificity of IRAP for the sulfonamides can, at least in part, be related to the particular configuration of its GAMEN loop typical for the open configuration of this enzyme.

![Binding modes of compound **26** (red sticks) in IRAP (gray cartoon) in pose *A* (A) and pose *B* (B). GAMEN loop of IRAP highlighted in red and overlaid with that of homologous proteases: APN (PDB code 4FYQ, light green) and LTA4H (PDB code 2VJ8, cyan), which show a predicted steric clash with the sulfonamide in either binding mode. Zn^2+^ is shown as gray sphere.](ao-2018-00595y_0005){#fig6}

Conclusions {#sec3}
===========

We have extended our previously reported series of sulfonamides as inhibitors of human IRAP by synthesis of novel fluorinated analogs and performed an enzymatic and computational structural analysis of their inhibitory activity toward human IRAP. The biological data reveals several inhibitors with activity in the sub-micrometer range. Earlier computations on a limited set of sulfonamides (**21**, **25**, and **26**) predicted two possible binding modes. Here, we examined the full series of 27 compounds by molecular dynamics free energy calculations using both the linear interaction energy method and free energy perturbation simulations. The calculations on this larger set of compounds allow us to unambiguously identify the most favorable pose of the two binding poses. We foresee that this analysis will be helpful in our efforts to further improve the inhibitory capacity of IRAP inhibitors.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

All chemicals were purchased from Sigma-Aldrich/Apollo scientific/Acros/Fluorochem and used as received without further purification. Purification was performed on a semipreparative Gilson GX-271 RP-HPLC system, equipped with a Macherey-Nagel Nucleodur C18 column (21 × 125 mm, 5 μm particle size) and a H~2~O/CH~3~CN/0.05% HCOOH gradient over 15 min. Analytical high-performance liquid chromatography mass spectrometry (HPLC-MS) was performed on a Dionex UltiMate 3000 HPLC-MS system with an ion trap mass spectrometer and detection was performed by UV (DAD) and MS (ESI^--^ or ESI^+^) using a Phenomenex Kinetex C18 column (50 × 3.0 mm, 2.6 μm particle size, 100 Å pore size) and a flow rate of 1.5 mL/min. A gradient of H~2~O/CH~3~CN/0.05% HCOOH was used.

^1^H and ^13^C NMR spectra were obtained on a Varian Mercury Plus spectrometer (^1^H: 400 MHz, ^13^C: 101 MHz) using CDCl~3~, CD~3~OD, acetone-*d*~6~, or DMSO-*d*~6~ as solvent. HRMS were recorded on a Micromass Q-Tof2 mass spectrometer equipped with an electronspray ion source. Compounds **8**--**26** were prepared according to the methods previously described.^[@ref51],[@ref52]^

General Procedure for the Synthesis of Compounds **27**--**34** {#sec4.2}
---------------------------------------------------------------

To a solution of 3-(1*H*-tetrazol-5-yl)aniline (**36**) (0.5 mmol) in anhydrous CH~2~Cl~2~ (5 mL) under an atmosphere of nitrogen was added appropriate sulfonyl chloride (**35**) (0.6 mmol) and pyridine (1.5 mmol). The resulting reaction mixture was stirred at room temperature overnight and then quenched with a saturated solution of NH~4~Cl (20 mL); the pH was adjusted to around 4 by the addition of 1 M aq HCl. The aqueous phase was extracted with CH~2~Cl~2~ (3 × 10 mL). The combined organic phases were dried over Na~2~SO~4~ and evaporated under reduced pressure. The residue obtained was purified by preparative HPLC running a gradient of H~2~O/CH~3~CN/0.05% HCOOH to give the corresponding products.

### *N*-(3-(1*H*-Tetrazol-5-yl)phenyl)-2,3,4-trichlorobenzenesulfonamide (**27**) {#sec4.2.1}

White solid, yield 58%. ^1^H NMR (400 MHz, methanol-*d*~4~) δ 8.08 (d, *J* = 8.7 Hz, 1H), 7.88 (ddd, *J* = 2.2, 1.7, 0.5 Hz, 1H), 7.67 (ddd, *J* = 7.7, 1.7, 1.1 Hz, 1H), 7.63 (d, *J* = 8.7 Hz, 1H), 7.43 (ddd, *J* = 8.2, 7.7, 0.5 Hz, 1H), 7.32 (ddd, *J* = 8.2, 2.3, 1.0 Hz, 1H). (101 MHz, methanol-*d*~4~) δ 156.14, 138.65, 137.79, 137.24, 133.69, 131.54, 130.28, 130.11, 128.33, 125.45, 122.83, 122.44, 118.22. HRMS (ES) *m*/*z* calcd for \[M + H\]^+^: C~13~H~8~Cl~3~N~5~O~2~S 401.9386; found 401.9390.

### *N*-(3-(1*H*-Tetrazol-5-yl)phenyl)-3,5-bis(trifluoromethyl)benzenesulfonamide (**28**) {#sec4.2.2}

White solid, yield 70%. ^1^H NMR (400 MHz, methanol-*d*~4~) δ 8.38 (m, 1H), 8.34 (m, 0.9 Hz, 1H), 7.95 (m, 1H), 7.90 (m, 1H), 7.60 (m, 1H), 7.41 (m, 1H). ^13^C NMR (101 MHz, methanol-*d*~4~) δ 156.22, 142.16, 137.84, 132,38 (q, *J*^C--F^ = 34.4 Hz), 130.28, 127.19 (m), 126.29 (m), 125.77 (m), 123.84, 123.61, 122.49 (q, *J*^C--F^ = 272.5 Hz), 119.72. HRMS (ES) *m*/*z* calcd for \[M + H\]^+^: C~15~H~9~F~6~N~5~O~2~S 436.0303; found 436.0294

### *N*-(3-(1*H*-Tetrazol-5-yl)phenyl)-2,5-bis(trifluoromethyl)benzenesulfonamide (**29**) {#sec4.2.3}

White solid, yield 51%. ^1^H NMR (400 MHz, methanol-*d*~4~) δ 8.47 (m, 1H), 8.27 (m, 1H), 8.19 (m, 1H), 7.97 (m, 1H), 7.86 (m, 1H), 7.58 (m, 1H), 7.43 (m, 1H). ^13^C NMR (101 MHz, methanol-*d*~4~) δ 156.25, 139.65 (m), 137.69, 133.80 (qq, *J*^C--F^ = 34.1, 0.8 Hz), 130.93 (qq, *J*^C--F^ = 33.9, 1.0 Hz), 130.17, 129.88 (qm, *J*^C--F^ = 3.7 Hz), 129.68 (qm, *J*^C--F^ = 6.4 Hz), 128.33 (qm, *J*^C--F^ = 3.8 Hz), 125.66, 123.43, 123.28, 122.53 (q, *J* = 272.6 Hz), 122.12 (q, *J* = 274.1 Hz), 119.24. HRMS (ES) *m*/*z* calcd for \[M + H\]^+^: C~15~H~9~F~6~N~5~O~2~S 436.0303; found 436.0308.

### *N*-(3-(1*H*-Tetrazol-5-yl)phenyl)-4-methyl-3-(trifluoromethyl)benzenesulfonamide (**30**) {#sec4.2.4}

White solid, yield 53% (0.33 mmol scale). ^1^H NMR (400 MHz, methanol-*d*~4~) δ 8.11 (m, 1H), 8.00 (m, 1H), 7.94 (m, 1H), 7.82 (m, 1H), 7.61 (m, 1H), 7.55 (m, 1H), 7.39 (m, 1H), 2.59 (m, 3H). ^13^C NMR (101 MHz, methanol-*d*~4~) δ 156.20, 142.30 (q, *J*^C--F^ = 1.5 Hz), 138.52, 137.65, 132.85, 130.21, 130.07, 129.12 (q, *J*^C--F^ = 30.8 Hz), 125.48, 124.18 (q, *J*^C--F^ = 5.9 Hz), 123.63 (q, *J*^C--F^ = 273.5 Hz), 123.25, 122.97, 119.11, 17.99 (q, *J*^C--F^ = 2.1 Hz). HRMS (ES) *m*/*z* calcd for \[M + H\]^+^: C~15~H~12~F~3~N~5~O~2~S 382.0586; found 382.0577.

### *N*-(3-(1*H*-Tetrazol-5-yl)phenyl)-3-methyl-4-(trifluoromethyl)benzenesulfonamide (**31**) {#sec4.2.5}

White solid, yield 29% (0.33 mmol scale). ^1^H NMR (400 MHz, methanol-*d*~4~) δ 7.97 (m, 1H), 7.92 (m, 1H), 7.87 (m, 2H), 7.82 (m, 1H), 7.55 (m, 1H), 7.40 (m, 1H), 2.59 (m, 3H). ^13^C NMR (101 MHz, methanol-*d*~4~) δ 156.32, 142.95, 138.45, 138.25, 132.22 (q, *J*^C--F^ = 30.5 Hz), 130.05, 130.00, 126.42 (q, *J*^C--F^ = 5.7 Hz), 125.61, 124.59, 123.72 (q, *J*^C--F^ = 273.5 Hz), 123.09, 122.95, 119.05, 17.97 (q, *J*^C--F^ = 2.2 Hz). HRMS (ES) *m*/*z* calcd for \[M + H\]^+^: C~15~H~12~F~3~N~5~O~2~S 382.0586; found 382.0581.

### *N*-(3-(1*H*-Tetrazol-5-yl)phenyl)-3-fluoro-4-(trifluoromethyl)benzenesulfonamide (**32**) {#sec4.2.6}

White solid, yield 22% (0.33 mmol scale). ^1^H NMR (400 MHz, methanol-*d*~4~) δ 7.89--7.82 (m, 2H), 7.80--7.72 (m, 3H), 7.47 (m, 1H), 7.30 (ddd, *J* = 8.1, 2.3, 1.0 Hz, 1H). ^13^C NMR (101 MHz, methanol-*d*~4~) δ 159.30 (dq, *J*^C--F^ = 260.4, 2.0 Hz), 156.32, 145.71 (dq, *J*^C--F^ = 6.7, 1.1 Hz), 138.02, 130.17, 128.32 (dq, *J*^C--F^ = 4.7, 1.1 Hz), 125.76, 123.33 (d, *J*^C--F^ = 1.6 Hz), 123.04 (d, *J*^C--F^ = 4.7 Hz), 122.95 (dq, *J*^C--F^ = 272.34, 1.1 Hz), 122.58 (dq, *J*^C--F^ = 33.5, 12.6 Hz), 119.30, 115.65, 115.41. HRMS (ES) *m*/*z* calcd for \[M + H\]^+^: C~14~H~9~F~4~N~5~O~2~S 386.0335; found 386.0345.

### *N*-(3-(1*H*-Tetrazol-5-yl)phenyl)-2-fluoro-5-(trifluoromethyl)benzenesulfonamide (**33**) {#sec4.2.7}

White solid, yield 55%. ^1^H NMR (400 MHz, methanol-*d*~4~) δ 8.15 (dd, *J* = 6.2, 2.3 Hz, 1H), 7.94 (m, 1H), 7.87 (m, 1H), 7.72 (ddd, *J* = 7.7, 1.7, 1.1 Hz, 1H), 7.51--7.43 (m, 2H), 7.35 (ddd, *J* = 8.2, 2.2, 1.1 Hz, 1H). (101 MHz, methanol-*d*~4~) δ 160.65 (dm, *J*^C--F^ = 262.1 Hz), 156.32, 137.80, 132.64 (dq, *J*^C--F^ = 10.0, 3.7 Hz), 130.08, 128.30 (d, *J*^C--F^ = 15.7 Hz), 127.95 (dq, *J*^C--F^ = 3.9, 1.1 Hz), 126.72 (dq, *J*^C--F^ = 34.1, 3.9 Hz), 125.68, 123.04 (d, *J*^C--F^ = 19.9 Hz), 122.96 (q, *J*^C--F^ = 271.7 Hz), 118.88, 118.33, 118.10. HRMS (ES) *m*/*z* calcd for \[M + H\]^+^: C~14~H~9~F~4~N~5~O~2~S 386.0335; found 386.0331.

### *N*-(3-(1*H*-Tetrazol-5-yl)phenyl)-3,4-difluorobenzenesulfonamide (**34**) {#sec4.2.8}

White solid, yield 53%. ^1^H NMR (400 MHz, methanol-*d*~4~) δ 7.73 (m, 1H), 7.68--7.61 (m, 2H), 7.55 (m, 1H), 7.38--7.27 (m, 2H), 7.19 (ddd, *J* = 8.1, 2.2, 1.0 Hz, 1H). (101 MHz, methanol-*d*~4~) δ 156.64, 152.93 (dd, *J*^C--F^ = 255.3, 12.3 Hz), 149.83 (dd, *J*^C--F^ = 252.6, 13.5 Hz), 138.33, 136.54, 130.02, 126.04, 124.53 (dd, *J*^C--F^ = 7.8, 4.0 Hz), 123.05, 123.03, 119.11, 117.94 (d, *J*^C--F^ = 18.8 Hz), 116.55 (dd, *J*^C--F^ = 20.1, 1.4 Hz). HRMS (ES) *m*/*z* calcd for \[M + H\]^+^: C~13~H~9~F~2~N~5~O~2~S 336.0367; found 336.0369.

Enzyme Assay {#sec4.3}
------------

The efficacy of the candidate compounds to inhibit IRAP enzymatic activity was analyzed using solubilized, crude membranes isolated from HEK293 cells (ATCC, Manassas, VA) transfected with pCI-IRAP. Membranes from vector-only transfected cells were used as a negative control. IRAP enzymatic activity was determined by the hydrolysis of the synthetic substrate [l]{.smallcaps}-leucine-4-methyl-7-coumarinylamide (Sigma-Aldrich, St Louis, MO) and monitored by the release of a fluorogenic product at excitation and emission wavelengths of 380 and 430 nm, respectively. Assays were performed in 96-well plates; each well contained 1 μg of solubilized membrane protein and 25 μM substrate in a final volume of 100 μL in 50 mM Tris--HCl buffer (pH 7.4). Reactions were performed at 37 °C for 30 min using a Wallac Victor3 V Multilabel counter (PerkinElmer, Waltham, MA). IC~50~ values for each of the inhibitors were determined over a range of concentrations (0.01--100 μM) and were calculated from three independent experiments, reporting the mean ± SEM.

Preparation of the IRAP Structure and Ligand Docking {#sec4.4}
----------------------------------------------------

The crystal structure of human IRAP was retrieved from the protein data bank (PDB code 4PJ6),^[@ref56]^ and chain A of the crystal dimer was retained and prepared for molecular dynamics (MD) simulations. The preparation of the structure (i.e., addition of hydrogens, rotamer assignment of Asn and His) was performed with Maestro version 9.2. (Schrödinger, LLC; NY). The series of sulfonamides was built in a reliable three-dimensional conformation with the same software, and each compound was docked by structural alignment ("flexible ligand superposition" protocol in Schrödinger) in each of the two binding modes (pose *A* and pose *B*) previously determined for compound **26**.^[@ref30],[@ref31]^ The last complex was superimposed to the crystal structures of the homologous enzymes APN and LTA4H (PDB codes 4FYQ([@ref58]) and 2VJ8,^[@ref59]^ respectively) using the PyMol^[@ref61]^ graphical interface, to analyze the structural reasons for selectivity.

Molecular Dynamics (MD) Simulations {#sec4.5}
-----------------------------------

MD simulations were performed under spherical boundary conditions using program Q,^[@ref62]^ allowing an efficient sampling of the free energies of many ligands at a low computational cost, while attaining reliable statistics.^[@ref63],[@ref64]^ The all-atom optimized potentials for liquid simulations force field for proteins was used,^[@ref65]^ in combination with compatible parameters for Zn^2+^ ion and automatic parameterization of the ligands, performed with Macromodel version 10.6 (Schrödinger LLC). A simulation sphere of 25 Å radius centered on the equivalent position of the Cα atom of His4 in Ang IV was built as previously described.^[@ref30],[@ref31]^ The sphere was solvated with TIP3P water molecules^[@ref66]^ and subjected to polarization and radial constraints according to the surface-constrained all-atom solvent model^[@ref62],[@ref67]^ to mimic the properties of bulk water at the sphere surface. Protein atoms outside the simulation sphere were restrained to their initial positions and only interacted with the system through bonds, angles, and torsions. Excluding His, all other titratable residues within 20 Å of the Zn^2+^ ion were treated in their charged form. In addition, the residues Lys520, Lys726, Glu767, Asp773, Arg817, Glu818, Arg820, Glu825, Arg858, Glu887, Lys890, Lys892, Glu895, Arg933, and Glu1002, in the 20--25 Å layer of the sphere, were also treated as ionized because they were forming salt bridges. With this setup, the simulation sphere was overall neutral, thus avoiding the consideration of additional Born terms in the calculation of free energies of charged ligands as compared to that of the bulk solvent. Nonbonded interactions were calculated explicitly up to a 10 Å cutoff, except for the ligand atoms for which no cutoff was used. Beyond the direct cutoff, long-range electrostatics were treated with the local reaction field multipole expansion method.^[@ref68]^ During a 175 ps equilibration stage, the system was slowly heated to the target temperature of 310 K while initial positional restrains on all solute heavy atoms were gradually released. The subsequent data collection phase consisted of 10 replica MD simulations of 2 ns each, with randomized initial velocities, accounting for a total of 20 ns sampling trajectories where the ligand-surrounding energies were collected for binding affinity calculations. A time step of 1 fs was used, and no positional restraints were applied. Solvent bonds and angles were constrained using the SHAKE algorithm.^[@ref69]^ Nonbonded pair lists were updated every 25 steps, and the ligand-surrounding interaction energies were sampled every 50 steps. To estimate free energies of binding, ligand-surrounding energies were also sampled in parallel MD simulations of the reference state, that, solvated in water, using the same conditions as for the bound state.

Linear Interaction Energy Binding Affinity Calculations {#sec4.6}
-------------------------------------------------------

Binding free energies of every compound were calculated using the linear interaction energy (LIE) method as^[@ref54],[@ref55]^where Δ⟨*U*~l-s~^vdW^⟩ and Δ⟨*U*~l-s~^el^⟩ are, respectively, the differences in the average nonpolar and polar ligand-surrounding interaction energies in the two states, that is, free and bound ligands. The coefficients α and β are scaling parameters^[@ref55],[@ref70],[@ref71]^ for the nonpolar and polar terms, respectively. In the standard LIE model, α has a value of 0.18, whereas β depends on the chemical nature of the ligand. The IRAP active site has a divalent Zn^2+^ ion together with a cluster of carboxylates, causing very large electrostatic interaction energies with the ligands. Because these interaction energies, particularly those involving the Zn^2+^ ion, will be very sensitive to the force field parameters, we follow a protocol used earlier for binding sites containing ions^[@ref57]^ and treated as a free parameter. An electrostatic correction term^[@ref62]^ was added to account for the long-range interactions of the charged sulfonamides with the neglected charges of the neutralized titratable residues. This term was calculated as Δ*G*~corr~^el^ = 0.64 kcal/mol following the relationshipwhere *q~p~* is the formal charge of the neglected ionic group, whereas *q~l~* is the partial charge of the ligand atom. The effective dielectric constant ε was set to 80. The last term γ is a protein-dependent constant that does not affect the relative binding free energies^[@ref70]^ but is used to offset the resulting calculated energies to the experimental values. The reported nonbonded energies correspond to average values over all 10 replicates, and the corresponding errors are calculated as the standard error of the mean (SEM).

Experimental binding free energies (Δ*G*~bind~^exp^) were extracted from IC~50~ values aswhere *c* is an assay-specific constant, which depends on the substrate concentration and the enzymatic *K*~m~ value.^[@ref72]^ This constant value does not affect the relative free energies and is implicitly included in the optimized value of γ in [eq [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"}.

Free Energy Perturbation {#sec4.7}
------------------------

The relative binding free energy between selected pairs of ligands, LIG~A~ and LIG~B~, was calculated using the free energy perturbation method. In this method, LIG~A~ is transformed into LIG~B~ in parallel MD simulations in both the bound and the reference (water-solvated) state, and the relative binding free energy is estimated via a standard thermodynamic cycle, where the free energy of binding is calculated as the difference in the free energy resulting in transforming each ligand pair, A, B, in both the bound and the solvated reference state asThe free energy difference associated with the transformation of ligands A to B was calculated using Zwanzig's exponential formula^[@ref73]^where *U*~*m*~ denotes the effective potential energy function of a particular FEP window and *n* is the number of intermediate states. *U*~*m*~ is constructed as a linear combination of the initial (A) and final (B) potentials of the subperturbationwhere the coupling parameter λ~*m*~ is stepwise incremented from 0 to 1, in our case divided into 51 λ-windows, where every window is sampled for 30 ps.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b00595](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b00595).Comparison of IC~50~ values of the sulfonamide series obtained in CHO and HEK293 cells; decomposition of the electrostatic and nonelectrostatic components of the free energy of binding for the LIE analyses; FEP transformations performed in pose A ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00595/suppl_file/ao8b00595_si_001.pdf))Structures of compounds **8**--**34** ([CSV](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00595/suppl_file/ao8b00595_si_002.csv))Crystallographic data ([ZIP](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00595/suppl_file/ao8b00595_si_003.zip))
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